Philip E. Hass
YOU?
Author Swipe
View article: Supplementary information from Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation
Supplementary information from Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation Open
Supplemental Methods: including HUVEC fibrin gel bead assay, Production of anti-DLL4 F(ab')2, Mouse neonatal retina assay, Xenograft tumor models, Histological analysis of mouse liver, PK assay methods, and Anti-therapeutic antibody assay …
View article: Data from Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation
Data from Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation Open
Purpose: Although agents targeting Delta-like ligand 4 (DLL4) have shown great promise for angiogenesis-based cancer therapy, findings in recent studies have raised serious safety concerns. To further evaluate the potential for therapeutic…
View article: Supplementary information from Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation
Supplementary information from Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation Open
Supplemental Methods: including HUVEC fibrin gel bead assay, Production of anti-DLL4 F(ab')2, Mouse neonatal retina assay, Xenograft tumor models, Histological analysis of mouse liver, PK assay methods, and Anti-therapeutic antibody assay …
View article: Data from Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation
Data from Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation Open
Purpose: Although agents targeting Delta-like ligand 4 (DLL4) have shown great promise for angiogenesis-based cancer therapy, findings in recent studies have raised serious safety concerns. To further evaluate the potential for therapeutic…
View article: Domain-Specific Antibodies Reveal Differences in the Membrane Topologies of Apolipoprotein L1 in Serum and Podocytes
Domain-Specific Antibodies Reveal Differences in the Membrane Topologies of Apolipoprotein L1 in Serum and Podocytes Open
Significance Statement Two variants of circulating APOL1, G1 and G2, protect against subspecies of Trypanosoma brucei infection, but concurrently confer a greater risk of CKD. Little is known about the topology of APOL1 in HDL particles or…
Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye Open
Innovative protein engineering and chemical conjugation technologies have yielded an impressive number of drug candidates in clinical development including >80 antibody drug conjugates, >60 bispecific antibodies, >35 Fc-fusion proteins and…
View article: Automated high throughput microscale antibody purification workflows for accelerating antibody discovery
Automated high throughput microscale antibody purification workflows for accelerating antibody discovery Open
To rapidly find "best-in-class" antibody therapeutics, it has become essential to develop high throughput (HTP) processes that allow rapid assessment of antibodies for functional and molecular properties. Consequently, it is critical to ha…
View article: Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye
Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye Open
To date, ocular antibody therapies for the treatment of retinal diseases rely on injection of the drug into the vitreous chamber of the eye. Given the burden for patients undergoing this procedure, less frequent dosing through the use of l…
View article: Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data
Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data Open
Binding interactions with the neonatal Fc receptor (FcRn) are one determinant of pharmacokinetic properties of recombinant human monoclonal antibody (rhumAb) therapeutics, and a conserved binding motif in the crystallizable fragment (Fc) r…